Tellimer

HY & Xover Update - CHEPDE, SAZGR, PROGRP

  • Cheplapharm: Strong 1Q21 resultsBuy the CHEPDE 3.5% 2/27 trading at 100.3/100.8
  • Nidda Healthcare: Fitch affirms its B rating with stable outlook on Nidda BondCoHold the SAZGR 5% 9/25 trading at 100.0/100.9
  • Progroup: Indications of additional capex in FY22Buy the PROGRP 3% 3/26 at a YTC Mar-22 of 2.1% and a YTM of 2.7%

Most Viewed See latest
Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers